Uncategorized
Aviceda Announces AVD-104, a Novel Glycomimetic Nanoparticle, Demonstrates Continued Clinical Safety in the Treatment of Geographic Atrophy Secondary to Macular Degeneration
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics, a privately held, late-stage clinical biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic non-resolving inflammation, announced today the recent presentation of positive data about AVD-104, its lead ophthalmic clinical asset, at the EURETINA congress held in Amsterdam, Netherlands, from October 4–7, 2023. The Phase 2/3 SIGLEC trial is currently underway evalua